Cargando…
Care Among Migraine Patients in a Commercially Insured Population
INTRODUCTION: Migraine management is characterized by the poor use of preventive therapy and the overuse of acute medications. An analysis of current treatment patterns in migraineurs is needed to improve care in this patient population. The aim of this study was to describe treatment patterns and h...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229133/ https://www.ncbi.nlm.nih.gov/pubmed/32062840 http://dx.doi.org/10.1007/s40120-020-00179-3 |
_version_ | 1783534699016093696 |
---|---|
author | Bonafede, Machaon McMorrow, Donna Noxon, Virginia Desai, Pooja Sapra, Sandhya Silberstein, Stephen |
author_facet | Bonafede, Machaon McMorrow, Donna Noxon, Virginia Desai, Pooja Sapra, Sandhya Silberstein, Stephen |
author_sort | Bonafede, Machaon |
collection | PubMed |
description | INTRODUCTION: Migraine management is characterized by the poor use of preventive therapy and the overuse of acute medications. An analysis of current treatment patterns in migraineurs is needed to improve care in this patient population. The aim of this study was to describe treatment patterns and healthcare utilization of newly diagnosed migraine patients. METHODS: This was a retrospective observation study of newly diagnosed migraine patients (no indication of migraine in the past year) identified in the IBM MarketScan Commercial Claims and Encounters database from 1 January 2010 to 30 June 2014. The final study population comprised persons aged 18–64 years at index (new diagnosis of migraine) with 12 months of continuous enrollment in an insurance plan with medical and pharmacy benefits pre-index and post-index. Treatment patterns and healthcare resource utilization were assessed during the post-index period (at least 12-months). RESULTS: Of the 1,588,666 migraine patients identified in the database as potentially eligible to participate in the study, 284,719 (17.9%) met the final inclusion criteria. Patients generally used acute and preventive therapies to manage migraine attacks, with most patients using preventive therapy (59.1%). However, 67.9% of those using preventive therapy discontinued the current therapy, with a median time to discontinuation of 5 months. Most of the patients who discontinued preventative therapy also used an acute treatment to manage migraine attacks after discontinuation (77.6%), generally in the year following discontinuation (68.4%). Patients on acute therapies were found to use triptans excessively (1.6%) and other non-migraine-specific acute medications for treatment (7.1%). Acute patients were also at risk of opioid dependence (12.0%) and commonly received opioids or barbiturates as first-line therapy (34.1%). CONCLUSION: Newly diagnosed migraine patients are not being properly treated, as indicated by their excessive use of acute therapies and short time on preventive treatment before discontinuation of that treatment. Further study of the reasons why patients discontinue preventive therapy (adverse events, no response, etc.) and continue to excessively use acute treatments once their treatment regimen has been established is needed. |
format | Online Article Text |
id | pubmed-7229133 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-72291332020-05-18 Care Among Migraine Patients in a Commercially Insured Population Bonafede, Machaon McMorrow, Donna Noxon, Virginia Desai, Pooja Sapra, Sandhya Silberstein, Stephen Neurol Ther Original Research INTRODUCTION: Migraine management is characterized by the poor use of preventive therapy and the overuse of acute medications. An analysis of current treatment patterns in migraineurs is needed to improve care in this patient population. The aim of this study was to describe treatment patterns and healthcare utilization of newly diagnosed migraine patients. METHODS: This was a retrospective observation study of newly diagnosed migraine patients (no indication of migraine in the past year) identified in the IBM MarketScan Commercial Claims and Encounters database from 1 January 2010 to 30 June 2014. The final study population comprised persons aged 18–64 years at index (new diagnosis of migraine) with 12 months of continuous enrollment in an insurance plan with medical and pharmacy benefits pre-index and post-index. Treatment patterns and healthcare resource utilization were assessed during the post-index period (at least 12-months). RESULTS: Of the 1,588,666 migraine patients identified in the database as potentially eligible to participate in the study, 284,719 (17.9%) met the final inclusion criteria. Patients generally used acute and preventive therapies to manage migraine attacks, with most patients using preventive therapy (59.1%). However, 67.9% of those using preventive therapy discontinued the current therapy, with a median time to discontinuation of 5 months. Most of the patients who discontinued preventative therapy also used an acute treatment to manage migraine attacks after discontinuation (77.6%), generally in the year following discontinuation (68.4%). Patients on acute therapies were found to use triptans excessively (1.6%) and other non-migraine-specific acute medications for treatment (7.1%). Acute patients were also at risk of opioid dependence (12.0%) and commonly received opioids or barbiturates as first-line therapy (34.1%). CONCLUSION: Newly diagnosed migraine patients are not being properly treated, as indicated by their excessive use of acute therapies and short time on preventive treatment before discontinuation of that treatment. Further study of the reasons why patients discontinue preventive therapy (adverse events, no response, etc.) and continue to excessively use acute treatments once their treatment regimen has been established is needed. Springer Healthcare 2020-02-15 /pmc/articles/PMC7229133/ /pubmed/32062840 http://dx.doi.org/10.1007/s40120-020-00179-3 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Bonafede, Machaon McMorrow, Donna Noxon, Virginia Desai, Pooja Sapra, Sandhya Silberstein, Stephen Care Among Migraine Patients in a Commercially Insured Population |
title | Care Among Migraine Patients in a Commercially Insured Population |
title_full | Care Among Migraine Patients in a Commercially Insured Population |
title_fullStr | Care Among Migraine Patients in a Commercially Insured Population |
title_full_unstemmed | Care Among Migraine Patients in a Commercially Insured Population |
title_short | Care Among Migraine Patients in a Commercially Insured Population |
title_sort | care among migraine patients in a commercially insured population |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229133/ https://www.ncbi.nlm.nih.gov/pubmed/32062840 http://dx.doi.org/10.1007/s40120-020-00179-3 |
work_keys_str_mv | AT bonafedemachaon careamongmigrainepatientsinacommerciallyinsuredpopulation AT mcmorrowdonna careamongmigrainepatientsinacommerciallyinsuredpopulation AT noxonvirginia careamongmigrainepatientsinacommerciallyinsuredpopulation AT desaipooja careamongmigrainepatientsinacommerciallyinsuredpopulation AT saprasandhya careamongmigrainepatientsinacommerciallyinsuredpopulation AT silbersteinstephen careamongmigrainepatientsinacommerciallyinsuredpopulation |